On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic. As COVID-19 has spread around the globe, BioQore has diligently focused its efforts on expanding high-quality testing to help be part of the solution.
BioQore uses GenScript's cPassTM blood test for assessing the qualitative detection of total neutralizing antibodies. The cPassTM Neutralizing Antibody (NAb) test identifies explicitly whether a person has functional neutralizing antibodies that specifically block the SARS-CoV-2 virus. The NAb immune response process is referred to as sterilizing immunity and is authorized by the FDA for Emergency Use.
BioQore offers COVID-19 rapid testing solutions with unparalleled speed and throughput using best-in-class rapid COVID-19 testing devices, allowing you to identify individuals with active COVID-19 infections BEFORE they enter your venue or event and become super spreaders.
Our rapid testing service is performed on-site at your location and provides results in under 30 minutes. We can test up to 1000 people per hour and offer volume discount pricing for groups greater than 500. We offer rapid RT-PCR, LAMP, and antigen tests; we only use technologies that have been authorized by the FDA for Emergency Use.
We employ an easy-to-use software platform that manages the entire testing process, from registration, to expeditiously moving people through the testing process, to providing electronic results and a digited ‘cleared’ pass that can be scanned to allows for those who have been tested negative and been “cleared” to enter the venue.
The software platform integrates and automates vaccination status, daily health screening questionnaires, and temperature checks.
Our healthcare experts consist of qualified medical technicians, physicians, infectious disease specialists, and logistic experts, all of whom are experienced in large-volume COVID test deployment, management, containment, and remediation.